JOURNAL 2775
Bioorganic and Medicinal Chemistry Reports
Year: 2023 Issue: 2 July-December
p.9 - 17
Viewed 707 times.
-
Kajeen Hassan Jasim
-
Ronak Haj Ersan
-
Noor Adnan Naeem
-
Lana Ziyad Sulayman
-
Rayan Sadiq
-
Nechervan Waheed
-
Jihan Hasan Jasim
-
Azheen Qasem
GRAPHICAL ABSTRACT
ABSTRACT
Thyroid dysfunction has been observed in COVID-19 patients, prompting investigations by endocrinologists. The management of thyroid disease may be affected by pandemic-related restrictions and healthcare reorganization. In this study, we explored the association between COVID-19 and thyroid problems in Iraqi patients, with a particular focus on potential gender-specific effects and the impact of COVID-19 treatment on thyroid function. Our results revealed that SARS-CoV-2 can lead to reversible thyroid dysfunction, including subclinical and atypical thyroiditis. Significantly, our study demonstrated that COVID-19 patients had lower levels of triiodothyronine (T3) and tetraiodothyronine (T4) compared to a healthy control group. Additionally, we found that TSH levels in COVID-19 patients were higher than in non-COVID-19 patient group. whereas the CRP and Il-6 levels were increased in COVID-19 patients in comparison to the control group (p<0.05). These findings highlight the heightened susceptibility of Iraqi women to develop thyroid-related conditions and associated issues in the context of COVID-19. Our study aimed to investigate the correlation of TSH, T4, T3 among COVID-19 survivors (150 Individuals; 75 Healthy and 75 who had COVID-19 virus). Our results suggest that COVID-19 virus may have an important impact on thyroid health and the hypothalamus-pituitary-thyroid (HPT) axis in women which might be aggravated by the severity and chronicity of the disease.
KEYWORDS- COVID-19
- SARS-CoV-2
- thyroiditis chronic lymphocytic
- hypothyroidism
- hyperthyroidism
